If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
A reduced lumen diameter consequently elevates the blood pressure within the arterioles. Conversely, decreased sympathetic activity within the vasomotor nerves causes vasodilation of the vessels thereby decreasing blood pressure.
=== Succinate-CoA ligase === Succinate-CoA ligase is a heterodimer composed of an invariant α-subunit and a substrate-specific ß-subunit, encoded by either SUCLA2 or SUCLG2. This combination results in either an ADP-forming succinate-CoA ligase (A-SUCL, EC 6.2.1.5) or a GDP-forming succinate-CoA ligase (G-SUCL, EC 6.2.1.4). The ADP-forming succinate-CoA ligase is potentially the only matrix enzyme generating ATP in the absence of a proton motive force, capable of maintaining matrix ATP levels under energy-limited conditions, such as transient hypoxia.
=== Generic names === Gonadorelin is the generic name of the drug and its INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, and JANTooltip Japanese Accepted Name, while gonadorelina is its DCITTooltip Denominazione Comune Italiana and gonadoréline is its DCFTooltip Dénomination Commune Française. The diacetate salt is known as gonadorelin acetate and this is its USANTooltip United States Adopted Name, BANMTooltip British Approved Name, and JANTooltip Japanese Accepted Name, while the hydrochloride salt is known as gonadorelin hydrochloride and this is its USANTooltip United States Adopted Name and BANMTooltip British Approved Name.
=== Physical therapy === During the immobilization period, it is important to keep the foot flexible by lightly stretching the foot and calf regularly. As the plantar fascia recovers, physical therapy exercises help stabilize the ankle and correct gait patterns that may have contributed to the tear. Stretching and strengthening exercises decrease the chance of reinjury.
Sources: en.wikipedia.org
=== Michael McDonald years === Under contract to release another album in 1976, the Doobies were at a crossroads. Their primary songwriter and singer remained unavailable, so they turned to McDonald and Porter for material to supplement that of Simmons. The resulting LP, Takin' It to the Streets, debuted a radical change in their sound. Their electric guitar-based rock and roll gave way to a more soft rock and blue-eyed soul sound, emphasizing keyboards and horns and subtler, more syncopated rhythms. Baxter contributed jazz-inflected guitar stylings reminiscent of Steely Dan, along with unusual, complex harmony and longer, more developed melody. Above all, McDonald's voice became the band's new signature sound. Takin' It to the Streets featured McDonald's title track and "It Keeps You Runnin'", both hits. (A second version of "It Keeps You Runnin'", performed by Carly Simon, appeared on her album Another Passenger, with the Doobies backing her.) Bassist Porter wrote and sang "For Someone Special" as a tribute to the absent Johnston. A greatest hits compilation, Best of the Doobies, followed before year's end. (In 1996, the Recording Industry Association of America certified Best of the Doobies "Diamond" for sales in excess of 10 million units.) Their new sound was further refined, and McDonald's dominant role cemented with 1977's Livin' on the Fault Line. It featured a recording of the Motown classic "Little Darling (I Need You)" and "Echoes of Love", which had been written by Willie Mitchell for, but not recorded by, Al Green.
=== Metalloproteins and inorganic cofactors === Metalloproteins—in which the active site is a transition metal ion (or metal-sulfide cluster) often coordinated by sulfur atoms of cysteine residues—are essential components of enzymes involved in electron transfer processes. Examples include plastocyanin (Cu2+) and nitrous oxide reductase (Cu–S). The function of these enzymes is dependent on the fact that the transition metal ion can undergo redox reactions. Other examples include many zinc proteins, as well as iron–sulfur clusters. Most pervasive are the ferrodoxins, which serve as electron shuttles in cells. In bacteria, the important nitrogenase enzymes contain an Fe–Mo–S cluster and is a catalyst that performs the important function of nitrogen fixation, converting atmospheric nitrogen to ammonia that can be used by microorganisms and plants to make proteins, DNA, RNA, alkaloids, and the other organic nitrogen compounds necessary for life. Sulfur is also present in molybdenum cofactor.
== Origin == The ribosome may have first originated as a protoribosome, possibly containing a peptidyl transferase centre (PTC), in an RNA world, appearing as a self-replicating complex that only later evolved the ability to synthesize proteins when amino acids began to appear. Studies suggest that ancient ribosomes constructed solely of rRNA could have developed the ability to synthesize peptide bonds. In addition, evidence strongly points to ancient ribosomes as self-replicating complexes, where the rRNA in the ribosomes had informational, structural, and catalytic purposes because it could have coded for tRNAs and proteins needed for ribosomal self-replication. Hypothetical cellular organisms with self-replicating RNA but without DNA are called ribocytes (or ribocells). As amino acids gradually appeared in the RNA world under prebiotic conditions, their interactions with catalytic RNA would increase both the range and efficiency of function of catalytic RNA molecules. Thus, the driving force for the evolution of the ribosome from an ancient self-replicating machine into its current form as a translational machine may have been the selective pressure to incorporate proteins into the ribosome's self-replicating mechanisms, so as to increase its capacity for self-replication.
At Nagapatnam, Pulicat, and elsewhere, the company purchased 8,000–10,000 slaves, the bulk of whom were sent to Ceylon, while a small portion were exported to Batavia and Malacca. Finally, following a long drought in Madurai and southern Coromandel, in 1673, which intensified the prolonged Madurai-Maratha struggle over Tanjavur and punitive fiscal practices, thousands of people from Tanjavur, mostly children, were sold into slavery and exported by Asian traders from Nagapattinam to Aceh, Johor, and other slave markets. In September 1687, 665 slaves were exported by the English from Fort St. George, Madras. And, in 1694–96, when warfare once more ravaged South India, a total of 3,859 slaves were imported from Coromandel by private individuals into Ceylon. The volume of the total Dutch Indian Ocean slave trade has been estimated to be about 15–30% of the Atlantic slave trade, slightly smaller than the trans-Saharan slave trade, and one-and-a-half to three times the size of the Swahili and Red Sea coast and the Dutch West India Company slave trades. According to Sir Henry Bartle Frere (who sat on the Viceroy's Council), there were an estimated 8 or 9 million slaves in India in 1841. About 15% of the population of Malabar were slaves. Slavery was legally abolished in the possessions of the East India Company by the Indian Slavery Act, 1843.
== Further reading == Danger on the high seas – whales, debris and weather just some of the obstacles in the Volvo Ocean Race – Steve Elling, The National, 9 October 2014 Mundle, Rob (2006). Life at the Extreme: The Volvo Ocean Race Round the World 2005-2006. Nomad Press. ISBN 978-0-97712-948-5. Mundle, Rob (2003). Ocean Warriors: The Thrilling Story of the 2001/2002 Volvo Ocean Race Round the World. HarperCollins. ISBN 978-0-06050-808-1.
Sources: en.wikipedia.org
== Related compounds == Later work showed that replacing the chlorine atom with a fluorine atom (2F-Viminol) or with a trifluoromethyl group produced a compound with twice the potency and half the acute toxicity. A later team at Zambon found that one isomer of a pyrrolidone analog is 318 times as potent as morphine in its analgesic activity in animal studies. A number of related compounds were also found to be active, allowing a QSAR model to be constructed.
== A new home for biochemistry in Liverpool == The world's first Biochemistry Department (originally employing the archaic term 'Bio-chemistry') opened its research doors in 1903 within the newly created Johnston Laboratories, forming an early biomedical hub with other buildings that homed the Nobel Prize winning neurophysiologist Sir Charles Sherrington, who coined the term synapse. The original buildings are still in use today by the university, although not for laboratory-based research. The public-health scientist and visionary Benjamin Moore, was the inaugural holder of the world's first chair in Biochemistry, named The Johnston Chair in honour of the local benefactor William Johnston, a prominent Liverpool businessman.
== References == ADA - CSII Diabetes Care 2004; 27: S110. ADA - Implications of the DCCT study Diabetes Care 2002; 25: 25–27. ADA - Implications of the UKPD Study Diabetes Care 2002; 25: 28–32. Bell D.S.H., Fernando O. (2000). "Improved glycemic control with use of CSII compared with MDI therapy". Endocrine Practice. 6 (5): 257–360. doi:10.4158/EP.6.5.357. PMID 11141585. Binder C., Lauritzen T., Faber O., Pramming S. (1984). "Insulin pharmacokinetics". Diabetes Care. 7 (2): 188–99. doi:10.2337/diacare.7.2.188. PMID 6376015. S2CID 29287604.{{cite journal}}: CS1 maint: multiple names: authors list (link) Bode B.W., Steed R.D., Davidson P.C. (1996). "Reduction in severe hypoglycemia with longterm CSII in type 1 diabetes". Diabetes Care. 19 (4): 324–7. doi:10.2337/diacare.19.4.324. PMID 8729154. S2CID 29779558.{{cite journal}}: CS1 maint: multiple names: authors list (link) Bode BW; et al. (1999). "Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: A pilot study". Diabetes Research and Clin Practice. 46 (3): 183–90. doi:10.1016/S0168-8227(99)00113-8. PMID 10624783. Diabetes Technol Ther. 2004;6(2):105-13. Boland E.A., Grey M.; et al. (1999). "CSII - a new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes". Diabetes Care. 22 (11): 1779–84. doi:10.2337/diacare.22.11.1779. PMID 10546007. Carlton F.B. (2000). "Recent advances in the pharmacologic management of diabetes mellitus". Emergency Medicine Clinics of North America. 18 (4): 745–53.
"Victims as Defenders: African Troops in the Rhodesian Defence System 1890–1980". Small Wars & Insurgencies. 2 (2): 240–275. doi:10.1080/09592319108422981. Molomo, Mpho G. (2009). "The Link between Sustainable Development and Security in Botswana". In Cawthra, Gavin (ed.). African Security Governance: Emerging Issues. Tokyo: United Nations University Press. pp. 131–156. ISBN 9789280811773. Melson, C. D. (2005). "Top Secret War: Rhodesian Special Operations". Small Wars and Insurgencies. 16 (1): 57–82. doi:10.1080/0959231042000322567. S2CID 145455177. Moorcraft, Paul L.; McLaughlin, Peter (1982). Chimurenga! The War in Rhodesia, 1965-1980. A Military history. Marshalltown, South Africa: Sygma/Collins. ISBN 0620062142. Moorcraft, P. L.; McLaughlin, P. (2010). The Rhodesian War: A Military History. Stackpole Books. ISBN 9780811707251. Morse, Stephen A. (2006). "Historical Perspectives of Microbial Bioterrorism". In Anderson, Burt; Friedman, Herman; Bendinelli, Mauro (eds.). Microorganisms and Bioterrorism. New York City: Springer. pp. 15–30. ISBN 9780387281568. O'Brien, Kevin (September 2001). "Counter-Intelligence for counter-revolutionary warfare: The South African police security branch 1979–1990". Intelligence and National Security. 16 (3): 27–59. doi:10.1080/02684520412331306200. S2CID 153561623. Palmer, Robin (October 1983). "Review: From Zimbabwe to Azania? A Review Article". African Affairs. 82 (329): 574–578. doi:10.1093/oxfordjournals.afraf.a097565. JSTOR 721219. Prokosh, Eric, ed. (1994). "Disappearances" and Political Killings: Human Rights Crisis of the 1990s.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.